CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo

Journal of Virology

Volumn 78, Issue 22, 2004, Pages 12344-12354

  Schlaepfer, Erika ^a   Audigé, Annette ^a   Von Beust, Barbara ^a   Manolova, Vania ^b   Weber, Markus ^a   Joller, Helene ^a   Bachmann, Martin F ^b   Kundig, Thomas M ^a   Speck, Roberto F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; OLIGODEOXYNUCLEOTIDE; SYNTHETIC DNA; TOLL LIKE RECEPTOR 9;

ARTICLE; CELL FUSION; CPG ISLAND; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOID TISSUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD4; CD4 LYMPHOCYTE COUNT; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV-1; HUMANS; LYMPHOID TISSUE; MEMBRANE GLYCOPROTEINS; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, CELL SURFACE; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN-2; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; VIRUS REPLICATION;

EID: 7644230107     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.22.12344-12354.2004     Document Type: Article

References (58)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Agatsuma, T., K. Abe, H. Furukawa, R. Koga, M. Koizumi, H. Hotoda, and M. Kaneko. 1997. Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a 6-mer modified oligonucleotide, R-95288. Antiviral Res. 34:121-130.
3. Agatsuma, T., I. Yamamoto, H. Furukawa, and T. Nishigaki. 1996. Guanine-rich oligonucleotide modified at the 5′ terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Antiviral Res. 31:137-148.
4. Audige, A., E. Schlaepfer, A. Bonanomi, H. Joller, M. C. Knuchel, M. Weber, D. Nadal, and R. F. Speck. 2004. HIV-1 does not provoke alteration of cytokine gene expression in lymphoid tissue after acute infection ex vivo. J. Immunol. 172:2687-2696.
5. Bafica, A., C. A. Scanga, M. L. Schito, S. Hieny, and A. Sher. 2003. Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2. J. Immunol. 171:1123-1127.
6. Barboric, M., R. M. Nissen, S. Kanazawa, N. Jabrane-Ferrat, and B. M. Peterlin. 2001. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol. Cell 8:327-337.
7. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
8. Bisset, L. R., S. Bosbach, Z. Tomasik, H. Lutz, J. Schupbach, and J. Boni. 2001. Quantification of in vitro retroviral replication using a one-tube real-time RT-PCR system incorporating direct RNA preparation. J. Virol. Methods 91:149-155.
9. Bonanomi, A., D. Kojic, B. Giger, Z. Rickenbach, L. Jean-Richard-Dit- Bressel, C. Berger, F. K. Niggli, and D. Nadal. 2003. Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. J. Immunol. Methods 283:27-43.
10. Bourke, E., D. Bosisio, J. Golay, N. Polentarutti, and A. Mantovani. 2003. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102:956-963.
11. Christopherson, C., Y. Kidane, B. Conway, J. Krowka, H. Sheppard, and S. Kwok. 2000. PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J. Clin. Microbiol. 38:630-634.
12. Chun, T. W., R. T. Davey, Jr., D. Engel, H. C. Lane, and A. S. Fauci. 1999. Reemergence of HIV after stopping therapy. Nature 401:874-875.
13. Detels, R., P. Tarwater, J. P. Phair, J. Margolick, S. A. Riddler, and A. Munoz. 2001. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 15:347-355.
14. Elkins, K. L., T. R. Rhinehart-Jones, S. Stibitz, J. S. Conover, and D. M. Klinman. 1999. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162:2291-2298.
15. Equils, O., M. L. Schito, H. Karahashi, Z. Madak, A. Yarali, K. S. Michelsen, A. Sher, and M. Arditi. 2003. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170:5159-5164.
16. Field, A. K. 1999. Oligonucleotides as inhibitors of human immunodeficiency virus. Curr. Opin. Mol. Ther. 1:323-331.
17. Gibson, S. J., J. M. Lindh, T. R. Riter, R. M. Gleason, L. M. Rogers, A. E. Fuller, J. L. Oesterich, K. B. Gorden, X. Qiu, S. W. McKane, R. J. Noelle, R. L. Miller, R. M. Kedl, P. Fitzgerald-Bocarsly, M. A. Tomai, and J. P. Vasilakos. 2002. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 218:74-86.
18. Harandi, A. M., K. Eriksson, and J. Holmgren. 2003. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77:953-962.
19. Hartmann, G., R. D. Weeratna, Z. K. Ballas, P. Payette, S. Blackwell, I. Suparto, W. L. Rasmussen, M. Waldschmidt, D. Sajuthi, R. H. Purcell, H. L. Davis, and A. M. Krieg. 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164:1617-1624.
20. Hayashi, T., S. P. Rao, K. Takabayashi, J. H. Van Uden, R. S. Kornbluth, S. M. Baird, M. W. Taylor, D. A. Carson, A. Catanzaro, and E. Raz. 2001. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun. 69:6156-6164.
21. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
22. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:4531-4537.
23. Iho, S., T. Yamamoto, T. Takahashi, and S. Yamamoto. 1999. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J. Immunol. 163:3642-3652.
24. Ito, T., R. Amakawa, and S. Fukuhara. 2002. Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Hum. Immunol. 63:1120-1125.
25. Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216.
26. Kadowaki, N., S. Ho, S. Antonenko, R. W. Malefyt, R. A. Kastelein, F. Bazan, and Y. J. Liu. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-869.
27. Karpov, A. V. 2001. Endogenous and exogenous interferons in HIV-infection. Eur. J. Med. Res. 6:507-524.
28. Keiser, P., N. Nassar, M. B. Kvanli, D. Turner, J. W. Smith, and D. Skiest. 2001. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J. Acquired Immune Defic. Syndr. 27:14-19.
29. Klimkait, T., F. Stauffer, E. Lupo, and C. Sonderegger-Rubli. 1998. Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system. Arch. Virol. 143:2109-2131.
30. Klinman, D. M., and D. Currie. 2003. Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides. Clin. Exp. Immunol. 133:227-232.
31. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
32. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
33. Krug, A., S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z. K. Ballas, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31:2154-2163.
34. McCallus, D. E., K. E. Ugen, A. I. Sato, W. V. Williams, and D. B. Weiner. 1992. Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. Viral Immunol. 5:163-172.
35. Moore, J. P., J. A. McKeating, R. A. Weiss, and Q. J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139-1142.
36. Muller, P. Y., H. Janovjak, A. R. Miserez, and Z. Dobbie. 2002. Processing of gene expression data generated by quantitative real-time RT-PCR. BioTechniques 32:1372-1379.
37. Olbrich, A. R., S. Schimmer, K. Heeg, K. Schepers, T. N. Schumacher, and U. Dittmer. 2002. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J. Virol. 76:11397-11404.
38. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
39. Pleskoff, O., M. Seman, and M. Alizon. 1995. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion. J. Virol. 69:570-574.
40. Richman, D. D. 2001. HIV chemotherapy. Nature 410:995-1001.
41. Scheller, C., A. Ullrich, K. McPherson, B. Hefele, J. Knoferle, S. Lamla, A. R. Olbrich, H. Stocker, K. Arasteh, M. ter, V., A. Rethwilm, E. Koutsilieri, and U. Dittmer. 2004. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J. Biol. Chem. 279:21897-21902.
42. Schlapfer, E., M. Fischer, P. Ott, and R. F. Speck. 2003. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS 17:1613-1620.
43. Schwartz, O., M. Alizon, J. M. Heard, and O. Danos. 1994. Impairment of T-cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein. Virology 198:360-365.
44. Sereti, I., and H. C. Lane. 2001. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. Clin. Infect. Dis. 32:1738-1755.
45. Stanley, M. A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27:571-577.
46. Stein, C. A., A. M. Cleary, L. Yakubov, and S. Lederman. 1993. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res. Dev. 3:19-31.
47. Stein, C. A., L. M. Neckers, B. C. Nair, S. Mumbauer, G. Hoke, and R. Pal. 1991. Phosphorothioate oligodeoxycytidine interferes with binding of HlV-1 gp120 to CD4. J. Acquired Immune Defic. Syndr. 4:686-693.
48. Stoddart, C. A., L. Rabin, M. Hincenbergs, M. Moreno, V. Linquist-Stepps, J. M. Leeds, L. A. Truong, J. R. Wyatt, D. J. Ecker, and J. M. McCune. 1998. Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide ISIS 5320. Antimicrob. Agents Chemother. 42:2113-2115.
49. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335-376.
50. Tomai, M. A., L. M. Imbertson, T. L. Stanczak, L. T. Tygrett, and T. J. Waldschmidt. 2000. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell. Immunol. 203:55-65.
51. Uhlmann, E., and J. Vollmer. 2003. Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Discov. Devel. 6:204-217.
52. Vasilakos, J. P., R. M. Smith, S. J. Gibson, J. M. Lindh, L. K. Pederson, M. J. Reiter, M. H. Smith, and M. A. Tomai. 2000. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204:64-74.
53. Wagner, H. 2002. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 5:62-69.
54. Wagner, T. L., C. L. Ahonen, A. M. Couture, S. J. Gibson, R. L. Miller, R. M. Smith, M. J. Reiter, J. P. Vasilakos, and M. A. Tomai. 1999. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191:10-19.
55. Wagner, T. L., V. L. Horton, G. L. Carlson, P. E. Myhre, S. J. Gibson, L. M. Imbertson, and M. A. Tomai. 1997. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 9:837-845.
56. Wild, C., T. Oas, C. McDanal, D. Bolognesi, and T. Matthews. 1992. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89:10537-10541.
57. Wyatt, J. R., T. A. Vickers, J. L. Roberson, R. W. Buckheit, Jr., T. Klimkait, E. DeBaets, P. W. Davis, B. Rayner, J. L. Imbach, and D. J. Ecker. 1994. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. USA 91:1356-1360.
58. Zimmermann, S., O. Egeter, S. Hausmann, G. B. Lipford, M. Rocken, H. Wagner, and K. Heeg. 1998. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160:3627-3630.